1	Maternal smoking DNA methylation risk score associated with health
2	outcomes in offspring of European and South Asian ancestry
3	
4	Wei Q. Deng <sup>1,2,3*</sup> , Nathan Cawte <sup>4</sup> , Natalie Campbell <sup>3</sup> , Sandi M. Azab <sup>3,5</sup> , Russell J de Souza <sup>3,5</sup> ,
5	Amel Lamri <sup>3,4</sup> , Katherine M. Morrison <sup>6</sup> , Stephanie A. Atkinson <sup>6</sup> , Padmaja Subbarao <sup>7</sup> , Stuart E.
6	Turvey <sup>8</sup> , Theo J. Moraes <sup>7,9</sup> , Koon K. Teo <sup>3,4,5</sup> , Piush Mandhane <sup>10</sup> , Meghan B. Azad <sup>11</sup> , Elinor
7	Simons <sup>12</sup> , Guillaume Pare <sup>4,5,13,14</sup> , Sonia S. Anand <sup>3,4,5*</sup>
8	
9	
10	1. Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton, Hamilton,
11	Canada.
12	2. Department of Psychiatry and Behavioural Neurosciences, McMaster University,
13	Hamilton, Canada.
14	3. Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton,
15	Canada.
16	4. Population Health Research Institute, David Braley Cardiac, Vascular and Stroke
17	Research Institute, Hamilton, Canada.
18	5. Department of Health Research Methods, Evidence, and Impact, McMaster University,
19	Hamilton, Canada.
20	6. Department of Pediatrics, McMaster University, Hamilton, Canada.
21	7. Department of Pediatrics, University of Toronto, Toronto, Canada.
22	8. Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
23	Vancouver, Canada

24	9. Program in Translational Medicine, SickKids Research Institute, Toronto, Canada
25	10. Department of Pediatrics, University of Alberta, Edmonton, Canada
26	11. Children's Hospital Research Institute of Manitoba, Department of Pediatrics and Child
27	Health, University of Manitoba, Winnipeg, Canada
28	12. Section of Allergy and Immunology, Department of Pediatrics and Child Health,
29	University of Manitoba, Canada
30	13. Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and
31	Stroke Research Institute, Hamilton, Canada
32	14. Department of Pathology and Molecular Medicine, McMaster University, Michael G.
33	DeGroote School of Medicine, Hamilton, Canada
34	
35	*Correspondence: <u>dengwq@mcmaster.ca;</u> <u>anands@mcmaster.ca</u>
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	

#### 46 Abstract

47 Maternal smoking has been linked to adverse health outcomes in newborns but the extent to 48 which it impacts newborn health has not been quantified through an aggregated cord blood DNA 49 methylation (DNAm) score. Here we examine the feasibility of using cord blood DNAm scores 50 leveraging large external studies as discovery samples to capture the epigenetic signature of 51 maternal smoking and its influence on newborns in White European and South Asian 52 populations. We first examined association between individual CpGs and cigarette smoking 53 during pregnancy, smoking exposure in two White European birth cohorts (n = 744). Several 54 previously reported genes for maternal smoking were supported, with the strongest and most consistent signal from the *GFI1* gene (6 CpGs with  $p < 5 \times 10^{-5}$ ). Leveraging established CpGs for 55 56 maternal smoking, we constructed a cord blood epigenetic score of maternal smoking that was 57 validated in one of the European-origin cohorts (n = 347). This score was then tested for 58 association with smoking status, secondary smoking exposure during pregnancy, and health 59 outcomes in offspring measured after birth in an independent white European (n = 397) and a 60 South Asian birth cohort (n = 504). The epigenetic maternal smoking score was strongly associated with smoking status during pregnancy (OR=1.09 [1.07,1.10],  $p=5.5\times10^{-33}$ ) and more 61 hours of self-reported smoking exposure per week (1.93 [1.27, 2.58],  $p=7.8\times10^{-9}$ ) in White 62 63 Europeans, but not with self-reported exposure (p > 0.05) in South Asians. The same score was 64 consistently associated with a smaller birth size (-0.37 $\pm$ 0.12 cm, p=0.0023) in the South Asian 65 cohort and a lower birth weight ( $-0.043\pm0.013$ kg, p=0.0011) in the combined cohorts. This cord 66 blood epigenetic score can help identify babies exposed to maternal smoking and assess its long-67 term impact on growth. Notably, these results indicate a consistent association between the 68 DNAm signature of maternal smoking and a small body size and low birthweight in newborns, in

both white European mothers who exhibited some amount of smoking and in South Asianmothers who themselves were not active smokers.

71

#### 72 Introduction

73 Maternal smoking has adverse effects on offspring health including pre-term delivery (1,2), 74 stillbirth (3), and low birth weight (4), and is associated with pregnancy complications such as 75 maternal higher blood pressure, and gestational diabetes (5). Consistent with the Developmental 76 Origins of Health and Disease (DOHaD) hypothesis, maternal smoking exposes the developing 77 fetus to harmful chemicals in tobacco that negatively impact the health of newborns, resulting in 78 early-onset metabolic diseases, such as childhood obesity (6–9). Yet self-reported smoking status 79 is subject to underreporting among pregnant women (10-12). This could subsequently impact the 80 effectiveness of interventions aimed at reducing smoking during pregnancy and may skew data 81 on the risks associated with maternal smoking.

82

83 DNA methylation is one of the most commonly studied epigenetic mechanisms by which 84 cells regulate gene expression, and is increasingly recognized for its potential as a biomarker 85 (13). Differential DNA methylation has been established as a reliable biochemical response to 86 cigarette smoking and was shown to capture the long-lasting effects of persistent smoking in ex-87 smokers (14–16). Recent large epigenome-wide association studies (EWAS) have robustly 88 identified differentially methylated cytosine-phosphate-guanine (CpG) sites associated with 89 adult smoking (15,17,18) and maternal smoking (19,20). Our recent systematic review of 17 cord 90 blood epigenome-wide association studies (EWAS) found that out of the 290 CpG sites reported 91 to be associated with at least one of the following: maternal diabetes, pre-pregnancy body mass

92 index (BMI), diet during pregnancy, smoking, and gestational age, 19 sites were identified in 93 more than one study and all of them associated with maternal smoking (21). Furthermore, these 94 findings have led to a more thorough investigation of the epigenetic mechanisms underlying 95 associations between well-established epidemiological exposures and outcomes, such as the 96 relationship between maternal smoking and birth weight in Europeans (20,22–25) and the less 97 studied African American populations (24) as well as between maternal diet and cardiovascular 98 health (26).

99

100 Only a handful of cohort studies were designed to assess the influence of maternal 101 exposures on DNA methylation changes in non-Europeans (24,27). It has been suggested that 102 systematic patterns of methylation (28), such as cell composition, could differ between 103 individuals of different ancestral backgrounds, which could in turn confound the association 104 between differential DNAm and smoking behaviours (29). These systematic differences also 105 contribute to different smoking-related methylation signals at individual CpGs (30). Thus, a 106 comparative study of maternal smoking exposure is a first step towards generalizing existing EWAS results to other populations and a necessary step towards addressing health disparities 107 108 that exist between populations due to societal privilege, including race or ethnicity and 109 socioeconomic factors.

110

A promising direction in epigenetic studies of adult smoking is the application of a methylation score (31); this strategy can also be applied to disseminate current knowledge on differential DNA methylation studies of maternal smoking. A methylation score is usually tissuespecific and combines information from multiple CpGs using statistical models (13). Reducing

the number of predictors and measurement noise in the data can lead to better statistical power and a more parsimonious instrument for subsequent analyses. It is also of interest to determine whether methylation scores demonstrate the capacity to predict outcomes in diverse human populations, given the presence of systematic differences in methylation patterns due to ancestral backgrounds (28).

120

121 In this paper, we investigated the epigenetic signature of maternal smoking on cord blood 122 DNA methylation in newborns, as well as its association with newborn and later life outcomes in 123 one South Asian which refers to people who originate from the Indian subcontinent, and two 124 predominantly European-origin birth cohorts. Similar to the Born in Bradford study (32), we 125 observed several differentiating epidemiological characteristics between South Asian and European-origin mothers. Notably, almost none of the South Asian mothers were current 126 127 smokers and had low smoking rates pre-pregnancy as compared to European mothers, which is 128 consistent with the broader trends of lower smoking rates in South Asian females (33). Another 129 relevant observation is the small birth size and low birth weight in the South Asian newborns. 130 These differences in newborn size and weight may be influenced by various factors, including 131 maternal nutrition, genetics, and socioeconomic status. Keeping these differences in mind, we 132 first conducted cohort-specific epigenetic association studies between available CpGs and 133 maternal smoking in the predominantly European-origin cohorts, benchmarking with previously 134 identified CpGs for maternal smoking and adult smoking. Second, we leveraged the reported 135 summary statistics from existing large EWASs to construct a methylation risk score (MRS) for 136 maternal smoking. The MRS was first internally validated in one of the European-origin cohorts 137 and then tested in a second independent European-origin cohort. Third, we examined the

association between maternal smoking MRS and newborn health outcomes, including length,
weight, BMI ponderal index, and early-life anthropometrics in both European and South Asian
cohorts.

141

142

#### 143 Materials and Methods

144

#### 145 **Study population**

146 The NutriGen Alliance is a consortium consisting of four prospective, population-based birth 147 cohorts that enrolled birthing mother and newborn pairs in Canada. Details of these cohorts have 148 been described elsewhere (34). The current investigation focused on i). European-origin 149 offspring from the population-based CHILD study who were selected for methylation analysis, 150 ii). The Family Atherosclerosis Monitoring In early life (FAMILY) study that is predominately 151 European-origin, and iii). The SouTh Asian biRth cohorT (START) study that is exclusively 152 comprised of people who originated from the Indian subcontinent known as South Asians. The 153 ethnicity of the parents was self-reported and recorded at baseline in all three cohorts. Biological 154 samples, clinical assessments, and questionnaires were used to derive health phenotypes and an 155 array of genetic, epigenetic, and metabolomic data. The superordinate goal of the NutriGen study 156 is to understand how nutrition, environmental exposures, and physical health of mothers impact 157 the health and early development of their offspring using a multi-omics approach.

158

#### 159 Methylation data processing and quality controls

160 Newborn cord blood samples were processed using two methylation array technologies. About 161 half of the START samples and selected samples from CHILD were hybridized to the Illumina 162 Human-Methylation450K BeadChip (HM450K) array, which covers CpGs in the entire genome 163 (35) The raw methylation data were generated by the Illumina iScan software and separately pre-164 processed for START and CHILD using the "sesame" R package following pipelines designed 165 for HM450K BeadChip (36). The FAMILY samples were profiled using a targeted array based 166 on the Infinium Methylation EPIC designed by the Genetic and Molecular Epidemiology 167 Laboratory (GMEL; Hamilton, Canada). The GMEL customized array includes ~3000 CpG sites 168 that were previously reported to associate with complex traits or exposures and was designed to 169 maximize discovery while keeping the costs of profiling epigenome-wide DNA methylation 170 down. The targeted methylation data were pre-processed using a customized quality control 171 pipeline and functions from the "sesame" R package recommended for EPIC.

172

173 Pre-processed data were then used to derive the  $\beta$ -value matrix, where each column gives 174 the methylation level at a CpG site as a ratio of the probe intensity to the overall probe intensity. 175 Additional quality control filters were applied to the final beta-value matrices to remove samples 176 with > 10% missing probes and CpG probes with > 10% samples missing. Cross-reactive probes 177 and SNP probes were removed as recommended for HM450 (37) and EPIC arrays (38,39). For 178 CpG probes with a missing rate <10%, mean imputation was used to fill in the missing values. 179 We further excluded samples that were either mismatches between reported sex and methylation-180 inferred sex or were duplicates. Finally, considering the low prevalence of smokers, we sought to 181 reduce spurious associations by removing non-informative probes that were either all 182 hypomethylated ( $\beta$ -value < 0.1) or hypermethylated ( $\beta$ -value > 0.9), which have been shown to

have less optimal performance (40). A summary of the sample and probe inclusion/exclusion is
shown in Supplementary Table 1. A detailed description of pre-processing and quality control
steps is included in Supplementary Material.

186

187 Cell-type proportions (CD8T, CD4T, Natural Killer cells, B cells, monocytes, granulocytes, and nucleated red blood cells) were estimated following a reference-based 188 189 approach developed blood (41) R for cord and using packages 190 "FlowSorted.CordBloodCombined.450k" and "FlowSorted.Blood.EPIC". All data processing 191 and subsequent analyses were conducted in R v.4.1.0 (42).

192

#### 193 Phenotype data processing and quality controls

194 At the time of enrollment, all pregnant women completed a comprehensive questionnaire that 195 collected information on prenatal diet, smoking, education, socioeconomic factors, physical 196 activities and health as detailed previously (43,44). Maternal smoking history (0=never smoked, 197 1=quit before this pregnancy, 2=quit during this pregnancy, or 3=current smoker) was assessed 198 during the second trimester (at baseline). Smoke exposure was measured as "number of hours 199 exposed per week". GDM was determined based on a combination of oral glucose tolerance test 200 (OGTT), self-report, and reported diabetic treatments (insulin, pills, or restricted diet). For South 201 Asian mothers in START, the same OGTT threshold as Born in Bradford (27,32) was used, 202 while the International Association of the Diabetes and Pregnancy Study Groups (IASDPSG) 203 criteria (45) for OGTT were used in CHILD and FAMILY cohorts. Mode of delivery 204 (emergency c-section vs. other) was collected at the time of delivery.

206 Newborn length and weight were collected immediately after birth and extracted from 207 medical chart. The newborns were then followed up at 1, 2, 3, and 5 years of age and provided 208 basic anthropometric measurements, including height, weight, hip and waist circumference, BMI, 209 sum of the skinfolds (triceps skinfold and subscapular skinfold). Additional phenotypes included 210 smoking exposures (hours per week) at home, potential allergy based on mother reporting any of: 211 eczema, hay fever, wheeze, asthma, food allergy (egg, cow milk, soy, other) for her child in 212 FAMILY and START, and asthma based on mother's opinion in CHILD ("In your opinion, does 213 the child have any of the following? Asthma").

214

#### 215 Phenotype and Methylation Data Consolidation

216 The current investigation examines the impact of maternal smoking or smoke exposure on DNA 217 methylation derived from newborn cord blood in START and the two predominately European 218 cohorts (CHILD and FAMILY). To maximize sample size in FAMILY and CHILD, we retained 219 either self-identified or genetically confirmed Europeans based on available genetic data 220 (Supplementary Table 1). The cohorts consist of representative population samples without 221 enrichment for any clinical conditions, though only singleton mothers were invited to participate. 222 For continuous phenotypes, an analysis of variance (ANOVA) using the F-statistics or a two-223 sample *t*-test was used to compare the mean difference across the three cohorts or two groups, 224 respectively. For categorical phenotypes, a chi-square test of independence was used to compare 225 the difference in frequencies of observed categories. Note that three of the categories under 226 smoking history in the START cohort had expected cell counts less than 5, and was thus 227 excluded from the comparison, the reported *p*-value was for CHILD and FAMILY.

The final analytical datasets, after combining the quality-controlled methylation data and phenotypic data, included 352, 411, and 504 mother-newborn pairs from CHILD, FAMILY, and START, respectively. Demographic characteristics and relevant covariates of the epigenetic subsample and the overall sample are summarized in Table 1 and Supplementary Table 2, respectively.

234

#### 235 Epigenome-Wide Association of Maternal Smoking in European Cohorts

236

237 Since there were no current smokers in START (Table 1), we tested the association between 238 maternal smoking and differential methylated sites in FAMILY (# of CpG = 2,544) and CHILD 239 (# of CpG = 200,050). The primary outcome variable was "current smoker", defined by mothers 240 self-identified as currently smoking during the pregnancy vs. those who never smoked or quit 241 either before or during pregnancy. We also included a secondary outcome variable "ever 242 smoker", defined by mothers who are current smokers or have quit smoking vs. those who never 243 smoked. A tertiary outcome was smoking exposure, measured by the number of hours per week 244 reported by the expectant mothers, and was available in all cohorts. We summarized the type of 245 analyses for different outcomes in Supplementary Table 3.

246

We first conducted a separate epigenetic association study in each cohort, testing the association between methylation  $\beta$ -values at individual CpGs and the smoking phenotype using either a logistic regression model for smoking status or a linear regression for smoking exposure as the outcome. The model adjusted for additional covariates including the estimated cord blood cell proportions, maternal age, social disadvantage index, which is a continuous composite

measure of social and economic exposures (46), mother's years of education, GDM, and parity.
The smoking exposure variable was skewed, and a rank-based transformation was applied to
mimic a standard normal distribution.

255

256 We then meta-analyzed association results for maternal smoking status in the European cohorts using an inverse variance-weighted fixed-effect model. The meta-analysis was conducted 257 258 for 2,112 CpGs that were available in both CHILD (profiled using HM450K) and FAMILY 259 (profiled using the targeted array). For the tertiary outcome, we conducted an inverse variance 260 meta-analysis including START using both a fixed-effect model. For each EWAS or meta-261 analysis, the false discovery rate (FDR) adjustment was used to control multiple testing and we 262 considered CpGs that passed an FDR-adjusted p-value < 0.05 to be relevant for maternal 263 smoking.

264

#### 265 Using DNA Methylation to Construct Predictive Models for Maternal Smoking

266

267 We sought to construct a predictive model in the form of a methylation risk score (MRS) using reported associations of maternal smoking. The proposed solution adapted the existing lassosum 268 269 method (47) that was originally designed for polygenic risk scores, where the matrix of SNP 270 genotypes (X) can be conveniently replaced by the  $\beta$ -value matrix. For more details, see the 271 Supplementary Material. Briefly, an objective function under elastic-net constraint was 272 minimized to obtain the elastic-net solution  $\gamma$ , where only summary statistics (b) and a scalar of 273 the covariance between the  $\beta$ -values of the CpGs (X'X) are needed. The tuning parameters  $\lambda_1$ and  $\lambda_2$  were chosen by validating on the observed smoking history (as a continuous outcome) in 274

275 CHILD that produced the most significant model. The optimized  $\lambda_1$  and  $\lambda_2$  were then used to 276 create a final model that entails a list of CpGs and their corresponding weights, which were then 277 used to calculate a MRS for maternal smoking in the FAMILY and START samples.

278

279 The summary statistics of the discovery EWAS were obtained from EWAS catalog 280 (http://www.ewascatalog.org/) reported under "PubMed ID 27040690" by Joubert and 281 colleagues (19). The summary statistics were restricted to the analysis "sustained maternal 282 smoking in pregnancy effect on newborns adjusted for cell composition". Of the 2620 maternal 283 smoking CpGs that passed the initial screening, 2,107 were available in CHILD but only 128 284 were common to CHILD, FAMILY, and START. To evaluate whether the targeted GMEL-EPIC 285 array design has comparable performance as the epigenome-wide array to evaluate the epigenetic 286 signature of maternal smoking, a total of three MRSs were constructed, two using the 128 CpGs 287 available in all cohorts – across the HM450K and targeted GMEL-EPIC arrays – and with either 288 CHILD (n = 347 with non-missing smoking history) or FAMILY (n = 397 with non-missing 289 smoking history) as the validation cohort, and another using 2,107 CpGs that were only available 290 in CHILD and START samples with CHILD as the validation cohort. The validation model 291 considered the continuous smoking history without modification as the outcome, while 292 accounting for covariates, which included the estimated cord blood cell proportions, maternal 293 age, social disadvantage index, mother's years of education, GDM, and parity. Henceforth, we 294 referred to these derived maternal smoking scores as the FAMILY targeted MRS, CHILD 295 targeted MRS, and the HM450K MRS, respectively. To benchmark and compare with existing 296 maternal smoking MRSs, we calculated the Reese score using 28 CpGs (48,49), Richmond 297 score using 568 CpGs (49), Rauschert score using 204 CpGs (50), Joubert score using all 2,620

298 CpGs with evidence of association for maternal smoking (19), and finally a three-CpG score for 299 air pollution (51). The details of these scores and score weight can be found in Supplementary 300 Table 4.

301

#### 302 Statistical analysis

303 For each cohort, we contrasted the three versions of the derived scores using an analysis of 304 variance analysis (ANOVA) along with pairwise comparisons using a two-sample *t*-test to 305 examine how much information might be lost due to the exclusion of more than 10-fold CpGs at 306 the validation stage, in all samples and in non-smokers. We also examined the correlation 307 structure between all derived and external MRSs using a heatmap summarizing their pairwise 308 Pearson's correlation coefficient. Then, we compared the mean difference of each MRS score 309 among smoking history using an ANOVA F-test and two-sample t-test to understand whether 310 there was a dosage dependence in the cord blood DNAm signature of maternal smoking. 311 Additionally, each score was tested against a binary outcome for current smoker vs. not, and two 312 continuous measures for smoking history and weekly smoking exposure. The binary outcome was tested using a logistic regression model and the predictive performance was assessed using 313 314 area under the receiver operating characteristic curve (AUC). The reported 95% confidence 315 interval for each estimated AUC was derived using 2,000 bootstrap samples. The continuous 316 outcome was examined using a linear regression model and its performance was quantified using 317 the adjusted  $R^2$ .

318

For the derived MRS, we empirically assessed whether a systematic difference existed in the resulting score with respect to all other derived scores. This was examined via pairwise mean

321 differences between the HM450 and other scores using a two-sample *t*-test and an overall test of 322 mean difference using an ANOVA F-test, among all samples and the subset of never smokers. 323 Finally, we tested the association between each maternal smoking MRS and smoking phenotypes 324 in mothers, as well as offspring phenotypes using a linear regression model, when applicable, 325 adjusting for the child's age at each visit. The association results were meta-analyzed for 326 phenotypes with homogeneous effects across the cohorts using a fixed-effect model. An FDR 327 adjustment was used to control the multiple testing of meta-analyzed associations between MRS 328 and 25 (or 23, depending on the number of phenotypes available in the cohort) outcomes, and we 329 considered association that passed an FDR-adjusted p-value < 0.05 to be relevant.

- 330
- 331
- 332 **Results**
- 333

#### 334 Cohort Sample Characteristics

335 The analyses included 763 European mother-child pairs with cord blood DNAm data from the 336 CHILD study (CHILD; n = 352)(52) and The Family Atherosclerosis Monitoring In earLY life 337 (FAMILY; n = 411) study (43), and 503 South Asian mother-child pairs from The SouTh Asian 338 biRth cohorT (START) study (44). We observed lower past smoking and missingness on 339 smoking history among pregnant women in START as compared to CHILD or FAMILY using 340 the epigenetic subsample (Table 1) and the overall sample (Supplementary Table 2). Pregnant 341 women in START were significantly different from CHILD or FAMILY in that they were on 342 average younger at delivery, had a lower BMI, and a higher rate of GDM, in line with other 343 cohort studies in South Asian populations (53,54). As compared to START, newborn infants

from CHILD and FAMILY had a longer gestational period, a higher birth weight, and a higher
BMI at birth (Table 1; Supplementary Table 2). We observed no difference between cohorts in
terms of parity or newborn sex in the epigenetic subsample (Table 1).

347

348 Within the European epigenetic subsample, of the 744 mother-newborn pairs with 349 complete smoking history data, 40 (5.3%) newborns were exposed to current maternal smoking, 350 which is on the lower end of the spectrum for the prevalence of smoking during pregnancy 351 (9.2%-32.5%) among Canadians (55). In addition, mothers who smoked during pregnancy were 352 on average younger, had fewer years of education, and had higher household exposure to 353 smoking (Supplementary Table 6). However, there was no statistically significant difference 354 between newborns exposed to current and none or previous smoking in terms of birth weight, 355 birth length, gestational age, or estimated cord blood cell proportions.

356

357

#### 358 Epigenetic Association of Maternal Smoking in White Europeans

359 The two predominantly White European cohorts, FAMILY (n = 397) and CHILD (n = 347), 360 contributed to the meta-analysis of maternal smoking for both the primary outcome of current 361 smoking (Figure 2-A) and the secondary outcome of ever smoking (Supplementary Figure 1). 362 The top associated CpGs with current maternal smoking were mapped to the growth factor 363 independent 1 (GFII) gene on chromosome 1, with cg12876356 as the lead (meta-analyzed effect = -1.11±0.22; meta-analyzed  $p = 2.6 \times 10^{-6}$ ; FDR adjusted p = 0.006; Table 2). There were 364 365 no CpGs associated with the ever-smoker status at an FDR of 0.05, though the top signal (cg09935388) was also mapped to the GFII gene (Pearson's  $r^2$  correlation with cg12876356 = 366

367 0.75 and 0.68 in CHILD and FAMILY, respectively; Supplementary Figure 1). The top 368 associated CpG from the meta-analysis of smoking exposure (hours per week) in the European-369 origin cohorts (Figure 2-B) was cpg01798813 on chromosome 17, which was also associated 370 with maternal smoking and was consistent in the direction of association (meta-analyzed effect = -0.18±0.04; meta-analyzed  $p = 1.4 \times 10^{-5}$ ; FDR adjusted p = 0.04; Table 2). There was no 371 372 noticeable inflation of empirical type I error in the association *p*-values from the meta-analysis, 373 with the median of the observed association test statistic roughly equal to the expected median 374 (Supplementary Figure 2). As a sensitivity analysis, we repeated the analysis for the continuous 375 smoking exposure under rank transformation vs. raw phenotype for the associated CpG in GFII 376 and examined the regression diagnostics (Supplementary Material), and found that the model 377 under rank-transformation deviated less from assumptions. Further, we observed consistency in 378 the direction of association for the 128 CpGs that overlapped between our meta-analysis and the 379 2,620 CpGs with evidence of association for maternal smoking (19) (Supplementary Figure 3). 380 Specifically, the Pearson's correlation coefficient for maternal smoking and weekly smoking 381 exposure was 0.72 and 0.60, respectively. The maternal smoking and smoking exposure EWASs 382 in CHILD alone did not yield any CpGs after FDR correction (Supplementary Figure 4).

383

384

#### 385 Methylation Risk Score (MRS) Captures Maternal Smoking and Smoking Exposure

The final MRSs, validated using CHILD European samples (n = 347), included 15 and 143 CpG markers (Supplementary Table 7) from the targeted array and the epigenome-wide HM450 array, respectively. Both produced methylation scores that were significantly associated with maternal smoking history (ANOVA F-test *p*-values = $1.0 \times 10^{-6}$  and  $2.4 \times 10^{-14}$  in CHILD and  $3.6 \times 10^{-16}$  and

 $<2.2\times10^{-16}$  in FAMILY; Figure 3, Supplementary Figure 5), and the best among alternative 390 391 scores for CHILD and FAMILY (Supplementary Table 5). With the exception of the air 392 pollution MRS, which only contained 3 CpGs (Supplementary Table 5), all remaining scores 393 were marginally associated with smoking history in both CHILD and FAMILY (Supplementary 394 Figure 5) and correlated with each other (Supplementary Figure 6). In particular, scores that were 395 derived using the Joubert EWAS as the discovery sample, including ours, had higher pairwise 396 correlation coefficients across the birth cohorts, with many of the CpGs mapping to the same 397 genes, such as AHRR, MYO1G, GFI1, CYP1A1, and RUNX3. There was no statistically 398 significant difference in mean between the two scores in any of the three cohorts (two-sample t-399 test ps > 0.6) or among non-smokers (two-sample t-test ps > 0.6; Supplementary Figure 7). Since 400 the HM450 score provides statistically more significant results in both CHILD and FAMILY 401 with smoking history, despite the reduction in CpGs included (only 26 out of 143 CpGs present 402 in FAMILY; Supplementary Table 5), we proceeded with the HM450 MRS model constructed 403 using the 143 CpGs in subsequent analyses.

404

405 The HM450 MRS was significantly associated with maternal smoking history in CHILD 406 and FAMILY (n = 397), but we failed to meaningfully validate the association in START (n =407 503; Figure 3) – not surprisingly – due to the low number of ever-smokers (n = 2). A weak dose-408 dependent relationship between the MRS and the four categories of maternal smoking status in 409 the severity of exposure ([0] = never smoked; [1] = quit before this pregnancy; [2] = quit during 410 this pregnancy; [3] = currently smoking) was present in CHILD but was not replicated in 411 FAMILY (Figure 3). The AUC for detecting current smokers were 0.95 (95% confidence 412 interval: 0.89–1) and 0.89 (95% CI: 0.83–0.94) in CHILD and FAMILY (Figure 3), respectively,

413 while the AUCs for detecting ever-smokers were 0.61 (95% CI: 0.54–0.67), 0.60 (95% CI: 414 [0.55,0.69]; Supplementary Table 5), and 0.82 (95% CI: [0.55,1]; Figure 3), respectively. As a 415 result, the epigenetic maternal smoking score was strongly associated with smoking status during pregnancy (OR=1.09, 95% CI: [1.07,1.10],  $p=1.96\times10^{-32}$ ) in the combined European cohorts. 416 417 Meanwhile, the maternal smoking MRS was significantly associated with increased number of 418 hours exposed to smoking per week in the two White European cohorts (1.93±0.33 hours per 1 unit of increase in MRS, FDR adjusted  $p = 1.2 \times 10^{-7}$ ; Supplementary Table 8; cohort specific 419  $p=5.4\times10^{-5}$  in CHILD and  $p=2.3\times10^{-5}$  in FAMILY; Table 3), but not in the South Asian birth 420 421 cohort (p = 0.58; Table 3).

422

Among individuals who had never smoked, no statistically significant mean difference was observed in the distribution of the combined methylation score between South Asian and European cohorts (Supplementary Table 9). These results provided empirical support for the portability of an European-derived maternal smoking methylation score to South Asian populations.

428

429

#### 430 Association between MRS and other phenotypes

The maternal smoking MRS was consistently associated with increasing weekly smoking exposure in children reported by mothers at the 1-year visit ( $0.44\pm0.15$ , p = 0.0044; Table 3) in CHILD, and at 3-year visit ( $0.86\pm0.26$ , p = 0.0037; Table 3) in FAMILY, but not in START as all mothers reported non-exposure to smoking in children. A higher maternal smoking MRS was significantly associated with smaller birth size ( $-0.37\pm0.12$ , p = 0.0023; Table 3) and height at 1,

436 2, and 5 year visits in the South Asian cohort (Table 3). We observed similar associations with 437 body size in the white European cohorts (heterogeneity p-values> 0.2), collectively, the MRS 438 was associated with a smaller birth size (-0.22 $\pm$ 0.07, p=0.0016; FDR adjusted p = 0.019; 439 Supplementary Table 8) in the combined European and South Asian cohorts. Meanwhile, a 440 higher maternal smoking MRS was also associated with a lower birth weight (-0.043 $\pm$ 0.013, p = 441 0.001: FDR adjusted p = 0.011; Supplementary Table 8) in the combined sample, though the 442 effect was weaker in START (-0.03 $\pm$ 0.02; p = 0.094; Table 3) as compared to the white 443 European cohorts.

444

445 The meta-analysis revealed no heterogeneity in the direction nor the effect size of 446 associations for body size and weight between populations at birth or at later visits 447 (heterogeneity p-values = 0.16–1; Supplementary Table 8). The association between the MRS 448 and several children phenotypes, including height or length, weight, and skinfolds, appeared to 449 persist with similar estimated effects throughout early developmental years (Supplementary 450 Table 8), albeit the most significant effects were at birth, and the significance attenuated at later 451 visits. We did not find any association with self-reported allergy or asthma in children at later 452 visits (Supplementary Table 8). Further, there was no evidence of association between the MRS 453 and any maternal outcomes (Supplementary Table 8).

454

455

#### 456 **Discussion**

458 We examined the epigenetic signature of maternal smoking and smoking exposure using 459 newborn cord blood samples from predominately European-origin and South Asian cohorts via 460 two strategies: an individual CpG-level EWAS approach, and a multivariate approach in the 461 form of a methylation score. The EWAS results replicated the association between maternal 462 smoking and CpGs in the GFI1 gene that is well described in the literature with respect to 463 smoking (15,17), maternal smoking (19,20,56,57), and birth weight (23). In the latter case, we 464 observed a significant association with maternal smoking history and smoking exposure in 465 European-origin newborns. Further, we noted a weak dose-dependent relationship between 466 maternal smoking history and the methylation score in one European cohort (CHILD) but this 467 was not replicated in the other (FAMILY). Since the timing and duration of maternal smoking 468 during pregnancy were not directly available, these differences could play a role in the 469 magnitude and specificity of DNA methylation changes in cord blood. Finally, the significant 470 association of the MRS with the newborn health metrics in START, in the absence of mothers' 471 active smoking, could be the result of underreporting of smoking, poor recall of the time of 472 quitting, and/or due to air pollution exposure (58), leading to oxidative stress. This suggests that 473 our cord blood DNAm signature of maternal smoking is perhaps not unique to cigarette smoking, 474 but captures similar biochemical responses, for example, via the aryl hydrocarbon receptor 475 (59,60). Our observation that a higher MRS was associated with lower birth weight and smaller 476 birth length in both ethnic populations is thus consistent with the established link between 477 oxidative stress and metabolic syndrome (61).

478

479 Contrary to DNA methylation studies of smoking in adults, where whole blood is often480 used as a proxy tissue, there are multiple relevant tissues for maternal smoking during pregnancy,

481 including the placenta of the mother, newborn cord blood, and children's whole blood. However, 482 methylation changes measured in whole blood or placenta of the mother, or cord blood of infants 483 showed substantially different patterns of association signals (62). There are several advantages 484 of using a cord blood based biomarker from the DoHaD perspective. Firstly, cord blood provides 485 a direct reflection of the *in utero* environment and fetal exposure to maternal smoking. 486 Additionally, since cord blood is collected at birth, it eliminates potential confounding factors 487 such as postnatal exposures that may affect maternal blood samples. Furthermore, studying cord 488 blood DNAm allows for the assessment of epigenetic changes specifically relevant to the 489 newborn, offering valuable information on the potential long-term health implications. 490 Meanwhile, methylation signals are known to be tissue-specific, thus it would be of interest for 491 future research to combine differential methylation patterns from all relevant tissue to assess the 492 immediate and long-term effects of maternal smoking. Another direction to further this line of 493 research is to explore postnatal factors that mitigate prenatal exposures, for example, 494 breastfeeding, which has been shown to have a protective effect against maternal tobacco 495 smoking (63). Indeed, more research is necessary to understand the critical periods of exposure 496 and the dose-response relationship between maternal smoking and cord blood DNA methylation 497 changes. Ongoing efforts to monitor the offspring and collect data in the next decade are in 498 progress to establish the long-term association between maternal smoking and cardio-metabolic 499 health (43,44). As such, the constructed MRS can facilitate future research in child health and 500 will be included as part of the generated data for others to access.

501

502 The strengths of this report include ethnic diversity, and fine phenotyping in a 503 prospective and harmonized way with follow-up at multiple early childhood stages. This work is

504 the first major multi-ancestry study that utilizes methylation scores to study maternal smoking 505 and examines their portability from European-origin populations to South Asians. The use of 506 MRS, as compared to individual CpGs, is a powerful tool to systematically investigate the 507 influence of DNA methylation changes and whether it has lasting functional consequences on 508 health outcomes. Our results converge with previous findings that epigenetic associations of 509 maternal smoking are associated with newborn health, and add to the small body of evidence that 510 these relationships extend to non-European populations and that different ancestral populations 511 can experience the early developmental periods differently.

512

513 A few limitations should be mentioned. In the context of existing epigenetic studies of 514 maternal smoking, we were not able to replicate signals in other well-reported genes such as 515 AHRR, CYP1A1, and MYO1G, however, the MRS was able to pick up signals from these genes 516 (Supplementary Table 7). This could be due to several reasons. First, the customized array with a 517 limited number of CpGs (<3,000) was designed in 2016 and many large EWASs on smoking and 518 maternal smoking conducted more recently had not been included. Nonetheless, we have shown 519 that from a multivariate perspective, the MRS constructed using a targeted approach that was 520 carefully designed can be equally powerful with the advantage of being cost-effective. Second, 521 contrary to existing EWASs where the methylation values are typically treated as the outcome, 522 and the exposure, such as smoking, as the predictor; we reversed the regression such that the 523 methylation levels were the predictors and smoking exposure as the outcome. This reverse 524 regression approach is robust and our choice to reverse the regression was motivated by the goal 525 of constructing a smoking score that combines the additive effects at multiple CpGs, which 526 would otherwise be unfeasible. Third, systematic ancestral differences in DNA methylation

527 patterns had been shown to vary at individual CpGs in terms of their association with smoking 528 (30). Converging with this conclusion, we also found the association with GFI1 to be most 529 consistent after adjusting for cell composition. Fourth, while it would be of interest to examine a 530 broader range of health outcomes in children, such as lung health and allergies, we were unable 531 to acquire and standardize this information across different cohorts. This aspect should be 532 considered in future study designs. Finally, maternal smoking is often associated with other 533 confounding factors, such as socioeconomic status, other lifestyle behaviours, and environmental 534 exposures. While we have done our best to control for well-known confounders that were 535 available by study design, as in all observational studies, we could not account for unknown 536 confounding effects. Finally, in recent years, maternal smoking is on a decline as a result of 537 changes in social norms and public health policies (64). This is also consistent with the lower smoking rates observed in our European cohorts (CHILD and FAMILY). Given the proportion 538 539 of current smokers, the effective sample size for a direct comparison between CHILD and 540 FAMILY, i.e. equivalently-powdered sample size of a balanced (50% cases, 50% controls) 541 design, were 41.7 and 104.7, respectively. While CHILD had a lower effective sample size, we 542 ultimately chose it for validating the methylation score to better cover the CpGs that were 543 significant in the discovery EWAS. A larger validation study will likely further boost the 544 performance of the methylation score and be considered in future research.

545

In conclusion, the epigenetic maternal smoking score we constructed was strongly associated with smoking status during pregnancy and self-reported smoking exposure in White Europeans, and with smaller birth size and lower birth weight in the combined South Asian and White European cohorts. The proposed cord blood epigenetic signature of maternal smoking has

550	the potential to identify newborns who were exposed to maternal smoking in utero and to assess
551	the long-term impact of smoking exposure on offspring health. In South Asian mothers with
552	minimal smoking behaviour, the relationship between the methylation score and negative health
553	outcomes in newborns is still apparent, indicating that DNA methylation response is sensitive to
554	smoking exposure, even in the absence of active smoking.
555	
556	
557	
558	
559	

#### 561 **Tables and Figure legends**

#### 562 Table 1. Characteristics of the epigenetic subsample (1,267 mother-newborn pairs) from the CHILD, FAMILY, START

#### 563 cohorts.

	Phenotypes	CHILD	FAMILY	START	ANOVA F-test or Chi- squared test P-value for differences	
		(N=352)	(N=411)	(N=504)		
Mother	Smoking History					
	never smoked	247 (70.2%)	253 (61.6%)	501 (99.4%)	<0.001*	
	quit before this pregnancy	72 (20.5%)	58 (14.1%)	1 (0.2%)		
	quit during this pregnancy	17 (4.8%)	57 (13.9%)	1 (0.2%)		
	currently smoking	11 (3.1%)	29 (7.1%)	0 (0%)		
	Missing	5 (1.4%)	14 (3.4%)	1 (0.2%)		
	Smoking Exposure (hr/week)					
	Mean (SD)	$0.97 (\pm 7.64)$	2.52 (± 12.83)	0.33 (± 2.67)	< 0.001	
	Missing	12 (3.4%)	5 (1.2%)	42 (8.3%)		
	Gestational Diabetes Mellitus					
	YES	16 (4.5%)	66 (16.1%)	183 (36.3%)	< 0.001	
	NO	336 (95.5%)	345 (83.9%)	320 (63.5%)		
	Missing	0 (0%)	0 (0%)	1 (0.2%)		
	Years of Education				< 0.001	
	Mean (SD)	16.96 (± 3.08)	16.85 (± 3.39)	15.81 (± 2.41)		
	Missing	7 (2.0%)	3 (0.7%)	0 (0%)		
	Mother's Age					
	Mean (SD)	32.69 (± 4.45)	31.86 (± 5.42)	30.12 (± 3.91)	< 0.001	
	Missing	4 (1.1%)	0 (0%)	0 (0%)		

Parity				
Mean (SD)	$0.72 (\pm 0.88)$	0.80 (± 1.02)	0.80 (± 0.81)	0.098
Missing	2 (0.6%)	0 (0%)	13 (2.6%)	
Pre-pregnancy BMI (kg/m2)				
Mean (SD)	24.78 (± 5.42)	26.46 (± 6.38)	23.71 (± 4.45)	< 0.001
Missing	132 (37.5%)	16 (3.9%)	2 (0.4%)	
Newborn Sex				
Male	194 (55.1%)	211 (51.3%)	239 (47.4%)	0.083
Female	158 (44.9%)	200 (48.7%)	265 (52.6%)	
Plant Based Diet				
Mean (SD)	$-0.48 (\pm 0.46)$	$0.19~(\pm 0.67)$	1.56 (± 1.14)	< 0.001
Missing	23 (6.5%)	36 (8.8%)	16 (3.2%)	
Health Conscious Diet				
Mean (SD)	0.21 (± 0.81)	-0.73 (± 0.73)	$-0.42 (\pm 0.79)$	< 0.001
Missing	23 (6.5%)	36 (8.8%)	16 (3.2%)	
Western Diet				
Mean (SD)	-0.15 (± 0.63)	1.06 (± 1.20)	-0.51 (± 0.65)	< 0.001
Missing	23 (6.5%)	36 (8.8%)	16 (3.2%)	
Gestational Age (weeks)				
Mean (SD)	39.53 (± 1.38)	39.44 (± 1.47)	39.20 (± 1.32)	< 0.001
Missing	4 (1.1%)	0 (0%)	0 (0%)	
Birth Length (cm)				
Mean (SD)	51.68 (± 2.52)	50.20 (± 2.16)	51.44 (± 2.69)	< 0.001
Missing	71 (20.2%)	10 (2.4%)	7 (1.4%)	
Birth Weight (kg)				
Mean (SD)	3.50 (± 0.49)	3.53 (± 0.50)	3.26 (± 0.46)	< 0.001
Missing	6 (1.7%)	0 (0%)	1 (0.2%)	

Newborn

	Newborn BMI (kg/m2)				
	Mean (SD)	13.11 (± 1.41)	13.94 (± 1.29)	12.31 (± 1.39)	< 0.001
	Missing	72 (20.5%)	10 (2.4%)	7 (1.4%)	
	Newborn Ponderal Index (kg/m3)				
	Mean (SD)	25.45 (± 3.14)	27.79 (± 2.55)	24.02 (± 3.17)	< 0.001
	Missing	72 (20.5%)	10 (2.4%)	7 (1.4%)	
Estimated cell					
proportions	CD8T				
	Mean (SD)	$0.01 (\pm 0.01)$	0.04 (± 0.03)	$0.02 (\pm 0.02)$	< 0.001
	CD4T				
	Mean (SD)	0.11 (± 0.06)	0.13 (± 0.06)	0.16 (± 0.07)	< 0.001
	NK				
	Mean (SD)	$0.02 (\pm 0.02)$	$0.03 (\pm 0.03)$	0.02 (± 0.03)	< 0.001
	Bcell				
	Mean (SD)	$0.02 (\pm 0.02)$	$0.04 (\pm 0.03)$	$0.04 (\pm 0.03)$	< 0.001
	Mono				
	Mean (SD)	$0.01 (\pm 0.02)$	$0.04 (\pm 0.03)$	0.03 (± 0.03)	< 0.001
	Gran				
	Mean (SD)	$0.80 (\pm 0.10)$	0.60 (± 0.13)	0.72 (± 0.14)	< 0.001
	nRBC				
	Mean (SD)	$0.08~(\pm 0.08)$	$0.12 (\pm 0.11)$	0.07 (± 0.11)	< 0.001
	MNLR				
	Mean (SD)	6.59 (± 6.00)	3.30 (± 3.14)	3.98 (± 3.08)	< 0.001
	Missing	6 (1.7%)	0 (0%)	3 (0.6%)	

\_\_\_\_\_

#### 564

565 Table 2. Meta-analysis results of association between CpGs and maternal smoking and smoking exposure that passed a

566 marginal p < 0.05 threshold after the false discovery rate correction in European cohorts.

			UCSC	Meta-analysis (CHILD and FAMILY)					Cohor associati	t-specific on P-value	ਕ Reported Ξ		
	CHR	HR Position	HR Position CpG Reference Gene				Standard Error	Association P-value	P-value for Effect Heterogeneity	FDR adjusted Association P-value	CHILD	FAMILY	Association EWAS catalo
	1	92481269	<u>cg12876356</u>	GFI1	-1.11	0.22	7.33E-07	0.51	0.0019	0.02	9.45E-06	MS;S; AC; B	
	1	92482032	<u>cg09935388</u>	GFI1	-1.15	0.24	2.26E-06	0.52	0.0029	0.02	2.71E-05	MS;GA; S; AG BMI; BW	
Maternal	1	92482405	<u>cg14179389</u>	GFI1	-1.48	0.32	5.03E-06	0.73	0.0035	0.01	1.12E-04	MS;S	
Smoking	1	92481144	<u>cg18146737</u>	GFI1	-0.92	0.20	5.58E-06	0.50	0.0035	0.04	3.95E-05	MS;S; AC; B	
	1	92480576	<u>cg09662411</u>	GFI1	-0.94	0.22	1.64E-05	0.29	0.0083	0.10	3.85E-05	MS;S	
	1	92481479	cg18316974	GFI1	-0.74	0.18	3.58E-05	0.33	0.0152	0.13	7.34E-05	MS;S; AC; B	
	17	2494783943	cg01798813	_	-0.83	0.21	1.09E-04	0.34	0.0395	0.02	0.0016	A; GA; BM	
Smoking	1	92482032	cg09935388	GFI1	-0.18	0.04	1.39E-05	0.23	0.04	0.15	2.45E-05	MS;GA; S; AC BMI; BW	
Exposure	17	2494783943	cg01798813	_	-0.18	0.04	3.30E-05	0.13	0.04	0.00035	0.013	A; GA; BMI	

567

568 MS: maternal smoking

569 GA: gestational age

570 AC: alcohol consumption

- 571 BMI: body mass index
- 572 T2D: type 2 diabetes
- 573 A: age
- 574 BW: birth weight
- 575
- 576 Table 3. Significant associations between maternal smoking methylation risk score and phenotypes in CHILD, FAMILY and
- 577 **START.**

		CHILD			FAMILY			START	
	Fixed Effect	Standard Error	Association P-value	Fixed Effect	Standard Error	Association P-value	Fixed Effect	Standard Error	Association P-value
Smoking exposure (hr/week)	1.64	0.40	5.40E-05	2.58	0.60	2.34E-05	0.07	0.12	0.58
(hr/week) 3-year Smoking exposure	0.44	0.15	0.0044	_	_	-	_	_	-
(hr/week)	_	_	_	1.15	0.39	0.0033	—	—	_
Gestational weight gain (kg)	-0.36	0.38	0.35	-0.62	0.26	0.017	-0.14	0.34	0.69
Gestational age (weeks)	1.64	0.40	6.32E-05	2.84	0.62	5.52E-06	0.07	0.12	0.59
Birth weight (kg)	-0.06	0.03	0.016	-0.04	0.02	0.096	-0.03	0.02	0.094
Birth length (cm)	-0.14	0.15	0.35	-0.10	0.10	0.33	-0.37	0.12	0.0023
1-year Height (cm)	-0.32	0.16	0.047	-0.34	0.14	0.019	-0.42	0.16	0.0079
2-year Height (cm) 5-year Height (cm)	<b>-0.13</b> -0.36	0.35 0.26	<b>0.72</b> 0.16	<b>-0.26</b> -0.43	<b>0.17</b> 0.26	<b>0.14</b> 0.095	<b>-0.57</b> -0.47	<b>0.21</b> 0.37	<b>0.0067</b> 0.21
3-year Skinfold thickness	0.48	0.19	0.014	0.94	0.26	3.46E-04	0.24	0.27	0.38

5-year Skinfold thickness	0.56	0.24	0.019	0.68	0.37	0.068	0.12	0.42	0.77

579

#### 580 Figure Legends:

#### 581 Figure 1. Schematic overview of the analytical pipeline for the cord blood DNAm maternal

- 582 smoking score and association study.
- 583 Figure 1-A) shows the epigenome-wide association studies conducted in the European cohorts
- 584 (CHILD and FAMILY); Figure 1-B) illustrated the workflow for methylation risk score (MRS)
- 585 construction using an external EWAS (Joubert et al., 2016) as the discovery sample and CHILD
- 586 study as the external validation study, while Figure 1-C) demonstrates the evaluation of the MRS
- 587 in two independent cohorts of white European (i.e. FAMILY) and South Asian (i.e. START).
- 588 The validated MRS was then tested for association with smoking specific, maternal, and children

589 phenotypes in CHILD, FAMILY, and START, as shown in Figure 1-D).

- <sup>590</sup> \* indicates cohort sample size including those with missing smoking history.
- 591

## Figure 2. Manhattan plots of the meta-analyzed association between cord blood DNAm and maternal smoking in Europeans.

594 Manhattan plots summarized the meta-analyzed association *p*-values between cord blood DNA 595 methylation levels and current maternal smoking (A) or smoking exposure (B) at a common set 596 of 2,114 CpG sites. The red line denotes the smallest -log10(*p*-value) that is below the FDR 597 correction threshold of 0.05. The red dots represent established associations with maternal 598 smoking reported in Joubert and colleagues (19).

599

Figure 3. Relationships between maternal smoking MRS and maternal smoking history
categories for each of the studies.

6	n	$\mathbf{r}$
υ	υ	4

603	Maternal smoking methylation score (y-axis) was shown as a function of maternal smoking
604	history (x-axis) in levels of severity for prenatal exposure for CHILD (A), FAMILY (B), and
605	START (C). Each severity level was compared to the never-smoking group and the
606	corresponding two-sample <i>t</i> -test <i>p</i> -value was reported. The analysis of variance via an F-test <i>p</i> -
607	value was used to indicate whether a mean difference in methylation score was present among all
608	smoking history categories. The sample size for START cohort was provided due to the low
609	counts in categories of any smoking. The area under the receiver operating characteristic curve
610	(AUC) for each study was shown in the lower panel.
611	
612	Supporting Information captions
613	
614	Supplementary Material.
615	
616	Suppl. Table 1. Quality controls for the inclusion/exclusion of samples and methylation
617	probes.
618	
619	Suppl. Table 2. Characteristics of the overall sample include 5176 mother-newborn pairs
620	from the CHILD, FAMILY, and START cohorts.
621	
622	Suppl. Table 3. A summary of available analyses and outcome variables in each cohort.
623	

624	Suppl. Table 4. A summary of the DNAm maternal smoking score derivation design and
625	results.
626	
627	Suppl. Table 5. Score weights for external DNAm maternal smoking scores.
628	
629	Suppl. Table 6. Characteristics of the epigenetic subsample from CHILD and FAMILY
630	cohorts stratified by smoking status.
631	
632	Suppl. Table 7. A summary of CpGs that contribute to the DNAm maternal smoking scores
633	and their weights.
634	
635	Suppl. Table 8. Association between maternal smoking methylation risk score and
636	phenotypes in CHILD, FAMILY and START.
637	Suppl. Table 9. Summary of mean difference in methylation risk scores between studies in
638	overall samples and those never smoked.
639	
640	
641	
642	
643	Supplementary Figure 1. Manhattan plots of the meta-analyzed association between cord
644	blood DNA methylation and ever maternal smoking in the combined European cohorts.
645	The meta-analyzed association <i>p</i> -values for ever maternal smoking and methylation levels at
646	2,114 CpG sites were summarized in the Manhattan plot. Ever maternal smoking was defined to

647 compare those who were currently smoking or quitted before or during this pregnancy vs. those 648 never smoked. The red line denotes the smallest  $-\log_{10}(p-value)$  that is below the FDR 649 correction threshold of 0.05. The red dots represent established associations with maternal 650 smoking reported in Joubert and colleagues (19).

651

Supplementary Figure 2. Quantile-quantile plots of the meta-analyzed association between
 cord blood DNA methylation and maternal smoking history, smoking exposure in the
 combined European cohorts.

Quantile-quantile plots summarized the association p-values between cord blood DNA methylation levels and current maternal smoking (A) or ever maternal smoking (B) or weekly smoking exposure (C) at 2,114 CpG sites. The red line (y=x) is the line of reference and the genomic inflation factor, calculated as the ratio between the observed median and the theoretical median of the association test statistics, was annotated for each outcome.

660

# Supplementary Figure 3. Scatterplots of meta-analyzed association effects for maternal smoking history or smoking exposure and reported effects of maternal smoking.

Panel A) is the scatterplot of meta-analyzed effects for maternal smoking in the combined CHILD and FAMILY cohorts (x-axis) vs. reported effects for maternal smoking in Joubert et al., 2016 (y-axis) for all CpGs present in CHILD, FAMILY, and Joubert et al., 2016 (# CpGs = 128); Panel B) is the scatterplot of meta-analyzed effects for weekly smoking exposure in the combined CHILD and FAMILY cohorts (x-axis) vs. reported effects for maternal smoking in Joubert et al., 2016 (y-axis) for all CpGs present in CHILD, FAMILY, and Joubert et al., 2016 (#CpGs = 128). The solid gray line is the best fitted line (95% confidence interval shown as the

670 shaded area) for the linear relationship between the effect sizes and the dashed gray line 671 represents the reference of y=x. (19)

- 672
- 673

# Supplementary Figure 4. Manhattan plots of the Epigenome-wide associations between cord blood DNAm and maternal smoking history, smoking exposure in CHILD. Manhattan plots summarized the association *p*-values between cord blood DNA methylation levels and current maternal smoking (A) or ever maternal smoking (B) or weekly smoking exposure (C) at 200,050 CpG sites. The red line denotes the smallest -log10(*p*-value) that is below the FDR correction threshold of 0.05. The red dots represent established associations with maternal smoking reported in Joubert and colleagues (19).

681

682 (19)

## Supplementary Figure 5. A comparison of results for derived and external maternal smoking MRSs.

685 Maternal smoking methylation score (y-axis) was shown as a function of maternal smoking 686 history (x-axis) in levels of severity ([0] = never smoked; [1] = quit before this pregnancy; [2] = 687 quit during this pregnancy; [3] = currently smoking) for prenatal exposure for each study. The 688 scores shown were validated in 1) CHILD, 2) CHILD but restricted to CpGs that were also 689 present on the targeted array, 3) FAMILY using CpGs on the targeted array. Each severity 690 level was compared to the never smoking group and the corresponding two sample *t*-test *p*-value 691 was reported. An omnibus test *p*-value to test whether a mean difference in methylation score 692 was present among all smoking history categories.

693

## Supplementary Figure 6. A heatmap of correlation between derived and external maternal smoking MRSs.

This heatmap illustrates the pairwise correlation between MRSs calculated in A) CHILD, B) FAMILY, and C) START. Each cell represents the correlation coefficient, ranging from -1 to 1, indicating the strength and direction of the association. A value of 1 signifies a perfect positive correlation, while -1 indicates a perfect negative correlation. Values closer to 0 suggest no correlation. The color gradient from deep blue (strong negative correlation), through white (no correlation), to deep red (strong positive correlation), visually encodes the strength of these relationships. The scores in the black box were derived using lassosum and internally validated.

703

#### 704 Supplementary Figure 7. Comparison of all methylation scores stratified by study.

The boxplots captured the standardized maternal smoking methylation scores (y-axis) stratified by study. The top panels summarized results for all samples in CHILD, FAMILY, and START, while the bottom panels summarized results for only those in CHILD, FAMILY, and START that never smoked. The *p*-values indicate the significance for a mean difference for each pairwise comparison between the HM450K score validated in CHILD with other scores using two-sample *t*-tests.

711

712

## 713 Acknowledgements

We express our sincere gratitude to all the participating families and the START, FAMILY, and
CHILD study teams, including interviewers, nurses, computer and laboratory technicians,
clerical workers, research scientists, volunteers, managers, and receptionists.

717

We would like to acknowledge the Genetic and Molecular Epidemiology Laboratory (GMEL), an associate of Hamilton Health Sciences and McMaster University, for their indispensable contributions to this work. The technical staff of GMEL conducted all epigenetic profiling, including sample processing and other technical operations.

722

We thank the members of the Nutrigen Alliance for providing the data: Sonia S. Anand;
Stephanie A. Atkinson; Meghan Azad; Allan B. Becker; Jeffrey Brook; Judah A Denburg;
Dipika Desai; Russell J. de Souza; Milan K. Gupta; Michael Kobor; Diana L. Lefebvre; Wendy
Lou; Piushkumar J. Mandhane; Sarah McDonald; Andrew Mente; David Meyre; Theo J. Moraes;
Katherine M. Morrison; Guillaume Paré; Malcolm R. Sears; Padmaja Subbarao; Koon K. Teo;
Stuart E. Turvey; Julie Wilson; Salim Yusuf; Gita Wahi; Michael A. Zulyniak.

729

This study was funded by the Canadian Institutes of Health Research Metabolomics Team Grant:
MWG-146332. Dr. Anand is supported by a Tier 1 Canada Research Chair in Ethnicity and CVD
and Heart, Stroke Foundation Chair in Population Health, a grant from the Canadian Partnership
Against Cancer, Heart and Stroke Foundation of Canada and Canadian Institutes of Health
Research. Dr. Azad is supported by a Tier 2 Canada Research Chair in the Developmental
Origins of Chronic Disease.

#### 736 Data availability statement

737	The summary statistics used to construct methylation risk scores are available from EWAS						
738	catalog at http://www.ewascatalog.org/?trait=maternal%20smoking%20in%20pregnancy with						
739	additional filters of PubMID 27040690 and analysis on "Sustained maternal smoking in						
740	pregnancy effect on newborns adjusted for cell composition".						
741							
742	Summary statistics generated in the current study, including a total of 8 primary association						
743	studies (three smoking phenotypes in three cohorts) and 3 sets of meta-analyzed results in						
744	Europeans are available upon request. All scripts to reproduce and validate the predictive model						
745	can be found at						
746	https://github.com/WeiAkaneDeng/EpigeneticResearch/tree/main/MaternalSmoking.						
747							
748	Conflicts of interest						
749	No conflict of interest.						
750							
751	Ethics Statement						
752	Ethical approval was obtained independently from the Hamilton Integrated Research Ethics						
753	Board: CHILD (REB 07-2929), FAMILY (REB 02-060), and START (REB 10-640). CHILD						
754	was additionally approved by the respective Human Research Ethics Boards at McMaster						
755	University, the Universities of Manitoba, Alberta, and British Columbia, and the Hospital for						

Sick Children. Legal guardians of each participant provided written informed consent. Written
informed consent was obtained from the parent/guardian (participating mother) for each study

separately. We also have now obtained additional ethics board approval from HiREB (REB

16592) for using the data from the three cohorts together without additional consent from the

760 participants.

## 761 **Reference**

- Stock SJ, Bauld L. Maternal smoking and preterm birth: An unresolved health challenge.
   Vol. 17, PLoS Medicine. 2020.
- Liu B, Xu G, Sun Y, Qiu X, Ryckman KK, Yu Y, et al. Maternal cigarette smoking before
  and during pregnancy and the risk of preterm birth: A dose–response analysis of 25
  million mother–infant pairs. PLoS Med. 2020;17(8).
- Marufu TC, Ahankari A, Coleman T, Lewis S. Maternal smoking and the risk of still birth:
  systematic review and meta-analysis. BMC Public Health. 2015;15(1).
- Ventura SJ, Hamilton BE, Mathews TJ, Chandra A. Trends and variations in smoking
  during pregnancy and low birth weight: Evidence from the birth certificate, 1990-2000.
  Pediatrics. 2003;111(5 II).
- 5. U.S. Department of Health and Human Services. The Health Consequences of Smoking—
  50 Years of Progress A Report of the Surgeon General. A Report of the Surgeon General.
  2014.
- Montgomery SM, Ekbom A. Smoking during pregnancy and diabetes mellitus in a British
  longitudinal birth cohort. Br Med J. 2002;324(7328).
- 778
  7. Toschke A, Koletzko B, Slikker W, Hermann M, von Kries R. Childhood obesity is associated with maternal smoking in pregnancy. Eur J Pediatr. 2002;161(8).
- 780 8. Oken E, Levitan EB, Gillman MW. Maternal smoking during pregnancy and child
  781 overweight: Systematic review and meta-analysis. Vol. 32, International Journal of
  782 Obesity. 2008.
- Philips EM, Santos S, Trasande L, Aurrekoetxea JJ, Barros H, von Berg A, et al. Changes
  in parental smoking during pregnancy and risks of adverse birth outcomes and childhood
  overweight in Europe and North America: An individual participant data meta-analysis of
  229,000 singleton births. PLoS Med. 2020;17(8).
- 10. England LJ, Grauman A, Qian C, Wilkins DG, Schisterman EF, Yu KF, et al.
  Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes. Nicotine and Tobacco Research. 2007;9(10).
- Shipton D, Tappin DM, Vadiveloo T, Crossley JA, Aitken DA, Chalmers J. Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: A retrospective, cross sectional study. BMJ (Online). 2009;339(7732).
- Salmasi G, Grady R, Jones J, McDonald SD. Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Vol. 89, Acta obstetricia et gynecologica Scandinavica. 2010.
- Yousefi PD, Suderman M, Langdon R, Whitehurst O, Davey Smith G, Relton CL. DNA
  methylation-based predictors of health: applications and statistical considerations. Vol. 23,
  Nature Reviews Genetics. 2022.
- Shenker NS, Ueland PM, Polidoro S, Van Veldhoven K, Ricceri F, Brown R, et al. DNA
  methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology.
  2013;24(5).

802 15. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al. 803 Epigenetic Signatures of Cigarette Smoking. Circ Cardiovasc Genet. 2016;9(5). 804 16. Guida F, Sandanger TM, Castagné R, Campanella G, Polidoro S, Palli D, et al. Dynamics 805 of smoking-induced genome-wide methylation changes with time since smoking cessation. 806 Hum Mol Genet. 2015:24(8). 807 17. Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI, et al. Comparison 808 of smoking-related DNA methylation between newborns from prenatal exposure and 809 adults from personal smoking. Epigenomics. 2019;11(13). 810 Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco 18. 811 Smoking Leads to Extensive Genome-Wide Changes in DNA Methylation. PLoS One. 2013 May 17;8(5). 812 813 19. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA 814 Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide 815 Consortium Meta-analysis. Am J Hum Genet. 2016;98(4). 816 20. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Hougaard DM, et al. 817 Variable DNA methylation in neonates mediates the association between prenatal 818 smoking and birth weight. Philosophical Transactions of the Royal Society B: Biological 819 Sciences. 2019;374(1770). 820 21. Akhabir L, Stringer R, Desai D, Mandhane PJ, Azad MB, Moraes TJ, et al. DNA 821 methylation changes in cord blood and the developmental origins of health and disease – a 822 systematic review and replication study. BMC Genomics. 2022;23(1). 823 22. Witt SH, Frank J, Gilles M, Lang M, Treutlein J, Streit F, et al. Impact on birth weight of 824 maternal smoking throughout pregnancy mediated by DNA methylation. BMC Genomics. 825 2018;19(1). 826 23. Küpers LK, Xu X, Jankipersadsing SA, Vaez A, La Bastide-van Gemert S, Scholtens S, et 827 al. DNA methylation mediates the effect of maternal smoking during pregnancy on 828 birthweight of the offspring. Int J Epidemiol. 2015;44(4). 829 24. Xu R, Hong X, Zhang B, Huang W, Hou W, Wang G, et al. DNA methylation mediates 830 the effect of maternal smoking on offspring birthweight: a birth cohort study of multi-831 ethnic US mother-newborn pairs. Clin Epigenetics. 2021;13(1). 832 Cardenas A, Lutz SM, Everson TM, Perron P, Bouchard L, Hivert MF. Mediation by 25. 833 Placental DNA Methylation of the Association of Prenatal Maternal Smoking and Birth Weight. Am J Epidemiol. 2019;188(11). 834 835 Murray R, Kitaba N, Antoun E, Titcombe P, Barton S, Cooper C, et al. Influence of 26. 836 maternal lifestyle and diet on perinatal DNA methylation signatures associated with 837 childhood arterial stiffness at 8 to 9 years. Hypertension. 2021;78(3). 838 27. Raynor P, Duley L, Small N, Tuffnell D, Wild C, Wright J, et al. Born in Bradford, a 839 cohort study of babies born in Bradford, and their parents: Protocol for the recruitment 840 phase. BMC Public Health. 2008;8. 841 Elliott HR, Burrows K, Min JL, Tillin T, Mason D, Wright J, et al. Characterisation of 28. 842 ethnic differences in DNA methylation between UK-resident South Asians and Europeans. 843 Clin Epigenetics [Internet]. 2022 Dec 1 [cited 2023 Mar 9];14(1). Available from: 844 https://pubmed.ncbi.nlm.nih.gov/36243740/ 845 29. Choquet H, Yin J, Jorgenson E. Cigarette smoking behaviors and the importance of ethnicity and genetic ancestry. Transl Psychiatry. 2021;11(1). 846

- 847 30. Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. Differences in
  848 smoking associated DNA methylation patterns in South Asians and Europeans. Clin
  849 Epigenetics. 2014;6(1).
- Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: A robust classifier to determine smoking status from DNA methylation data. Epigenomics.
  2019;11(13).
- 853 32. Wright J, Small N, Raynor P, Tuffnell D, Bhopal R, Cameron N, et al. Cohort profile: The
  854 born in bradford multi-ethnic family cohort study. Int J Epidemiol. 2013;42(4).
- Reitsma MB, Flor LS, Mullany EC, Gupta V, Hay SI, Gakidou E. Spatial, temporal, and
  demographic patterns in prevalence of smoking tobacco use and initiation among young
  people in 204 countries and territories, 1990–2019. Lancet Public Health. 2021;6(7).
- de Souza RJ, Zulyniak MA, Desai D, Shaikh MR, Campbell NC, Lefebvre DL, et al.
  Harmonization of food-frequency questionnaires and dietary pattern analysis in 4
  ethnically diverse birth cohorts. Journal of Nutrition. 2016;146(11).
- 861 35. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA
  862 methylation array with single CpG site resolution. Genomics. 2011;98(4).
- 36. Zhou W, Triche TJ, Laird PW, Shen H. SeSAMe: Reducing artifactual detection of DNA
  methylation by Infinium BeadChips in genomic deletions. Nucleic Acids Res.
  2018;46(20).
- 866 37. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al.
  867 Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium
  868 HumanMethylation450 microarray. Epigenetics. 2013;8(2).
- 38. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative
  use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45(4).
- 871 39. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical
  872 evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome
  873 DNA methylation profiling. Genome Biol. 2016;17(1).
- 40. Hillary RF, McCartney DL, McRae AF, Campbell A, Walker RM, Hayward C, et al.
  Identification of influential probe types in epigenetic predictions of human traits:
  implications for microarray design. Clin Epigenetics. 2022;14(1).
- 41. Gervin K, Salas LA, Bakulski KM, Van Zelm MC, Koestler DC, Wiencke JK, et al.
  Systematic evaluation and validation of reference and library selection methods for
  deconvolution of cord blood DNA methylation data. Clin Epigenetics. 2019;11(1).
- R Core Team. R core team (2021). R: A language and environment for statistical
  computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www. Rproject. org. 2021.
- 43. Morrison KM, Atkinson SA, Yusuf S, Bourgeois J, McDonald S, McQueen MJ, et al. The
  Family Atherosclerosis Monitoring In earLY life (FAMILY) study. Rationale, design, and
  baseline data of a study examining the early determinants of atherosclerosis. Am Heart J.
  2009;158(4).
- 44. Anand SS, Vasudevan A, Gupta M, Morrison K, Kurpad A, Teo KK, et al. Rationale and
  design of South Asian Birth Cohort (START): A Canada-India collaborative study. BMC
  Public Health. 2013;13(1).
- 45. Metzger BE. International Association of Diabetes and Pregnancy Study Groups
  recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Vol.
  33, Diabetes Care. 2010.

- 46. Anand SS, Razak F, Davis AD, Jacobs R, Vuksan V, Teo K, et al. Social disadvantage
  and cardiovascular disease: Development of an index and analysis of age, sex, and
  ethnicity effects. Int J Epidemiol. 2006;35(5).
- Mak TSH, Porsch RM, Choi SW, Zhou X, Sham PC. Polygenic scores via penalized
  regression on summary statistics. Genet Epidemiol. 2017;(February):469–80.
- 898 48. Reese SE, Zhao S, Wu MC, Joubert BR, Parr CL, Håberg SE, et al. DNA methylation
  899 score as a biomarker in newborns for sustained maternal smoking during pregnancy.
  900 Environ Health Perspect. 2017;125(4).
- 901 49. Richmond RC, Suderman M, Langdon R, Relton CL, Smith GD. DNA methylation as a marker for prenatal smoke exposure in adults. Int J Epidemiol [Internet]. 2018 Aug 1
  903 [cited 2023 Mar 9];47(4):1120–30. Available from:
- 904 https://academic.oup.com/ije/article/47/4/1120/5026413
- 805 50. Rauschert S, Melton PE, Burdge G, Craig J, Godfrey KM, Holbrook JD, et al. Maternal
  806 smoking during pregnancy induces persistent epigenetic changes into adolescence,
  807 independent of postnatal smoke exposure and is associated with cardiometabolic risk.
  808 Front Genet. 2019;10(JUL).
- 909 51. Gondalia R, Baldassari A, Holliday KM, Justice AE, Méndez-Giráldez R, Stewart JD, et
  910 al. Methylome-wide association study provides evidence of particulate matter air
  911 pollution-associated DNA methylation. Environ Int. 2019;132.
- 52. Subbarao P, Anand SS, Becker AB, Befus AD, Brauer M, Brook JR, et al. The Canadian
  Healthy Infant Longitudinal Development (CHILD) study: Examining developmental
  origins of allergy and asthma. Thorax. 2015;70(10).
- 915 53. Brydon P, Smith T, Proffitt M, Gee H, Holder R, Dunne F. Pregnancy outcome in women
  916 with type 2 diabetes mellitus needs to be addressed. Int J Clin Pract. 2000;54(7).
- 54. Farrar D, Fairley L, Santorelli G, Tuffnell D, Sheldon TA, Wright J, et al. Association
  between hyperglycaemia and adverse perinatal outcomes in south Asian and white British
  women: analysis of data from the Born in Bradford cohort. Lancet Diabetes Endocrinol
  [Internet]. 2015 Oct 1 [cited 2023 Jun 8];3(10):795. Available from:
  /pmc/articles/PMC4673084/
- 55. Lange S, Probst C, Rehm J, Popova S. National, regional, and global prevalence of
  smoking during pregnancy in the general population: a systematic review and metaanalysis. Lancet Glob Health. 2018;6(7).
- 56. Markunas CA, Xu Z, Harlid S, Wade PA, Lie RT, Taylor JA, et al. Identification of DNA
  Methylation Changes in Newborns Related to Maternal Smoking during Pregnancy.
  Environ Health Perspect. 2014;122(10).
- 928 57. Richmond RC, Simpkin AJ, Woodward G, Gaunt TR, Lyttleton O, McArdle WL, et al.
  929 Prenatal exposure to maternal smoking and offspring DNA methylation across the
  930 lifecourse: Findings from the Avon Longitudinal Study of Parents and Children
  931 (ALSPAC). Hum Mol Genet. 2015;24(8).
- 8. Rider CF, Carlsten C. Air pollution and DNA methylation: Effects of exposure in humans.
  Vol. 11, Clinical Epigenetics. 2019.
- 934 59. Vogel CFA, Van Winkle LS, Esser C, Haarmann-Stemmann T. The aryl hydrocarbon
  935 receptor as a target of environmental stressors Implications for pollution mediated stress
  936 and inflammatory responses. Vol. 34, Redox Biology. 2020.

937	60.	Reynolds LM, Wan M, Ding J, Taylor JR, Lohman K, Su D, et al. DNA Methylation of
938		the Aryl Hydrocarbon Receptor Repressor Associations with Cigarette Smoking and
939		Subclinical Atherosclerosis. Circ Cardiovasc Genet. 2015;8(5).
940	61.	Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Vol. 84, Life Sciences.
941		2009.
942	62.	Everson TM, Vives-Usano M, Seyve E, Cardenas A, Lacasaña M, Craig JM, et al.
943		Placental DNA methylation signatures of maternal smoking during pregnancy and
944		potential impacts on fetal growth. Nat Commun. 2021;12(1).
945	63.	Moshammer H, Hutter HP. Breast-feeding protects children from adverse effects of
946		environmental Tobacco smoke. Int J Environ Res Public Health. 2019;16(3).
947	64.	Martin JA, Osterman MJK, Driscoll AK. Declines in Cigarette Smoking During
948		Pregnancy in the United States, 2016-2021. NCHS Data Brief. 2023;(458).
949		
950		

## A) Epigenome-Wide Association Study in European cohorts







Chromosome

Chromosome

chrX

S S



0.75

0.50

specificity

0.25

0.00

1.00

0.75

1.00

0.50

0.25

0.00

1.00

0.75

		AUC =	0.82			
_						
	0.	<b>5</b> 0	0.	25	0.0	00